Anavex Life Sciences (AVXL) vs. Syneos Health (SYNH) Financial Analysis

Anavex Life Sciences (NASDAQ: AVXL) and Syneos Health (NASDAQ:SYNH) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.


How to Become a New Pot Stock Millionaire

This table compares Anavex Life Sciences and Syneos Health’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Anavex Life Sciences N/A -69.24% -62.66%
Syneos Health -5.18% 10.78% 4.22%

Insider and Institutional Ownership

22.8% of Anavex Life Sciences shares are owned by institutional investors. 12.1% of Anavex Life Sciences shares are owned by company insiders. Comparatively, 0.2% of Syneos Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Anavex Life Sciences and Syneos Health’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Anavex Life Sciences N/A N/A -$13.46 million ($0.33) -6.12
Syneos Health $2.67 billion 1.50 -$138.46 million $1.94 19.82

Anavex Life Sciences has higher earnings, but lower revenue than Syneos Health. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Syneos Health, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Anavex Life Sciences has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Syneos Health has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Anavex Life Sciences and Syneos Health, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anavex Life Sciences 0 0 3 0 3.00
Syneos Health 0 3 7 0 2.70

Anavex Life Sciences presently has a consensus price target of $8.67, suggesting a potential upside of 329.04%. Syneos Health has a consensus price target of $50.88, suggesting a potential upside of 32.31%. Given Anavex Life Sciences’ stronger consensus rating and higher possible upside, analysts clearly believe Anavex Life Sciences is more favorable than Syneos Health.


Anavex Life Sciences beats Syneos Health on 7 of the 13 factors compared between the two stocks.

About Anavex Life Sciences

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases. The Company’s SIGMACEPTOR Discovery Platform produced small molecule drug candidates with unique modes of action. Sigma receptors may be targets for therapeutics to combat many human diseases, including Alzheimer’s disease. When bound by the appropriate ligands, sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease.

About Syneos Health

Syneos Health, Inc. operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process. The Commercial Solutions segment provides commercialization services, including outsourced field selling solutions, medication adherence, communications, and consulting services. Its customers include small, mid-sized, and large companies in the pharmaceutical, biotechnology, and medical device industries. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Raleigh, North Carolina.

Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with's FREE daily email newsletter.

Leave a Reply